Dr. Laura Sena discusses bipolar androgen therapy for prostate cancer

“This is different from other standard-of-care therapies for prostate cancer because usually we are inhibiting androgen receptor (AR) activity and here we’re actually stimulating AR,” explained Laura Anne Sena, MD, PhD.

In an interview during the SUO 2023 Annual Meeting, Laura Anne Sena, MD, PhD, explained the technique of bipolar androgen therapy for the treatment of patients with prostate cancer. Sena is an instructor of oncology at Johns Hopkins Medicine.